GBIO vs. QNTM, CCCC, CRBP, OPTN, FBRX, SAVA, TNYA, VIRI, ZNTL, and HLVX
Should you be buying Generation Bio stock or one of its competitors? The main competitors of Generation Bio include Quantum Biopharma (QNTM), C4 Therapeutics (CCCC), Corbus Pharmaceuticals (CRBP), OptiNose (OPTN), Forte Biosciences (FBRX), Cassava Sciences (SAVA), Tenaya Therapeutics (TNYA), Virios Therapeutics (VIRI), Zentalis Pharmaceuticals (ZNTL), and HilleVax (HLVX). These companies are all part of the "pharmaceutical products" industry.
Generation Bio vs. Its Competitors
Quantum Biopharma (NASDAQ:QNTM) and Generation Bio (NASDAQ:GBIO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.
Quantum Biopharma has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Comparatively, Generation Bio has a beta of 2.59, indicating that its stock price is 159% more volatile than the S&P 500.
Generation Bio has a consensus price target of $7.33, indicating a potential upside of 2,007.28%. Given Generation Bio's stronger consensus rating and higher probable upside, analysts plainly believe Generation Bio is more favorable than Quantum Biopharma.
In the previous week, Quantum Biopharma had 5 more articles in the media than Generation Bio. MarketBeat recorded 5 mentions for Quantum Biopharma and 0 mentions for Generation Bio. Quantum Biopharma's average media sentiment score of 0.56 beat Generation Bio's score of 0.00 indicating that Quantum Biopharma is being referred to more favorably in the media.
Quantum Biopharma has higher earnings, but lower revenue than Generation Bio. Quantum Biopharma is trading at a lower price-to-earnings ratio than Generation Bio, indicating that it is currently the more affordable of the two stocks.
1.2% of Quantum Biopharma shares are owned by institutional investors. Comparatively, 95.2% of Generation Bio shares are owned by institutional investors. 8.5% of Quantum Biopharma shares are owned by insiders. Comparatively, 21.8% of Generation Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Quantum Biopharma has a net margin of 0.00% compared to Generation Bio's net margin of -292.92%. Generation Bio's return on equity of -75.84% beat Quantum Biopharma's return on equity.
Summary
Generation Bio beats Quantum Biopharma on 11 of the 15 factors compared between the two stocks.
Get Generation Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for GBIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Generation Bio Competitors List
Related Companies and Tools
This page (NASDAQ:GBIO) was last updated on 7/3/2025 by MarketBeat.com Staff
Free GBIO Stock Alerts